ProEncia Biotechnology has secured significant pre-seed funding, marking its first external investment round. The capital will be used to advance its pipeline of novel, non-invasive periodontal care products, aiming for commercialization and licensing. While specific investor names and the exact funding amount were not disclosed, the company plans to leverage this investment to address the global burden of periodontal disease, which affects over one billion people worldwide.